Summary
BeOne Medicines Ltd. (ONC) has filed its 2025 Interim Report for the six months ended June 30, 2025, with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. This report, prepared in accordance with Chinese Accounting Standards (CAS) and other PRC GAAP, provides additional financial information for the reporting period. Investors should note that PRC GAAP differs from U.S. GAAP, and a reconciliation of material differences, along with research and development expenses allocated by key products and projects prepared under U.S. GAAP, is provided as Exhibit 99.1 to this 8-K filing. The primary purpose of this filing is to disclose financial information prepared under local Chinese accounting standards. While the full interim report is available in Chinese on the Shanghai Stock Exchange website, the attached Exhibit 99.1 is crucial for U.S. investors as it details R&D expenses under U.S. GAAP and highlights the differences between the two accounting frameworks. Investors are encouraged to review Exhibit 99.1 for a clearer understanding of the company's financial performance, particularly R&D investments, as they evaluate the company's progress.
Key Highlights
- 1BeOne Medicines Ltd. filed its 2025 Interim Report for the six months ended June 30, 2025, with the Shanghai Stock Exchange STAR Market.
- 2The interim report is prepared in accordance with China Accounting Standards (CAS) and other PRC GAAP.
- 3A key exhibit (99.1) provides U.S. GAAP financial information for research and development expenses, broken down by key products and projects.
- 4Exhibit 99.1 also details the material differences between PRC GAAP and U.S. GAAP.
- 5The full interim report is available in Chinese on the Shanghai Stock Exchange website (www.sse.com.cn).
- 6Information furnished in this 8-K is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- 7This filing is primarily for disclosure of local accounting standard-based financial information and U.S. GAAP R&D expense details.